Tweets
Gilead Sciences and EVOQ Therapeutics have a new 2023 partnership to develop immunotherapies for RA & SLE - using NanoDisc technology with lymph-targeted delivery of disease-specific-antigens. Gilead has IRAK4 inhibitor, GS-5718in Phase I https://t.co/kanUXUhMSm https://t.co/ZaDH1ueWrl
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Hydroxychloroquine significantly lowers Alzheimer’s and dementia risk. Study of g 109,124 #RA pts starting HCQ or MTX. showed an 8-16% lower risk. https://t.co/q516bZPOq5 https://t.co/2xdOa8pVAv
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/m8cdJgM7UC
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Retrospective Claims analysis 1663 #SLE pts shows pts w/ lupus nephritis (LN, 2916) had higher Charlson Comorbidity scores ≥4 (72 vs 14%) & inpatient (41 vs 17%). LUPUS FLARES were more (61 vs 54%), more severe (11 vs 5%) & twice the cost https://t.co/tXI7SSalaV https://t.co/z0SorOQilb
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Medical (AKA surgical) masks are not inferior to N95 fitted masks. A study of 1009 medical workers in 4 countries caring for COVID+ infected patients shows equal rate of PCR+ COVID tests (10.5% vs 9.3% +) (HR 1.14 [95% CI, 0.77 to 1.69]) https://t.co/wTuLHcOxlO https://t.co/gjqfLOU7JW
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
2002-2019 Canadian study of Rheumatology care: access has improved but problems exist, esp w/ DMARD use. In 112,494 new RA pts, 84% saw Rheum <1yrs w/ 43% increase by 2019. Suboptimal DMARD use in elderly improved 55 to 69% https://t.co/tpv514P0GP https://t.co/AIRuf7u60d
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/D0eQWcON2J https://t.co/rK77lCmbVv https://t.co/5X0e6DBxAh https://t.co/ZpJtc8SdcG
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/22DhyJUeuo
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Welcome, January 2023 ❄️.
It's the 50th year of the publication @jrheum ✨🎊!
View the full issue online
👉 https://t.co/GsZdjMZF1T
#rheumatoidarthritis #spondyloarthritis #psoriaticarthritis #lupus #vasculitis #pediatric #gout #rheumatology #50thyearofpublication #jrheum50 https://t.co/keUVRVD8vW
The Journal of Rheumatology @jrheum ( View Tweet )
3 years 6 months ago
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/D2GYjbR7y2
#BestOf2022
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
INBUILD Study of 170 pts with autoimmune related ILD showed nintedanib signifi. slowed the rate of FVC decline in FVC decline over 52 wks (NIN -75.9 mL/yr vs PBO -178.6 mL/yr). AE's (mostly diarrhea) leading to D/C was NIN 17.1% vs PBO 10.2% https://t.co/CmbF5NQMfJ #BestOf2022
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
608 EARLY RA pts in BARFOT study had Xrays over time. 24% did not show Erosions after 8 yrs. Pt w/ NO Erosions were younger, younger, w Less ACR criteria, & seronegative at Dx. They had more TJC, less SJC, lower ESR, less DMARDs & pred Rx. https://t.co/5jYNd7bwE3 https://t.co/z3Y0TPJTwd
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
